ADH-503 is primarily used as a selective inhibitor of the enzyme autotaxin (ATX), which plays a key role in the production of lysophosphatidic acid (LPA). LPA is a bioactive lipid involved in various cellular processes including proliferation, migration, and survival. By inhibiting autotaxin, ADH-503 reduces LPA levels, making it a valuable compound in research focused on fibrotic diseases and cancer. It has shown promise in preclinical models of idiopathic pulmonary fibrosis (IPF), liver fibrosis, and certain cancers where LPA signaling contributes to disease progression. Due to its ability to penetrate tissues effectively and modulate the LPA pathway, ADH-503 is widely used in experimental settings to study the pathophysiology of fibrosis and tumor microenvironment dynamics. Its selectivity and pharmacokinetic profile make it suitable for in vivo studies aiming to validate autotaxin as a therapeutic target.